Researchers Identified B Cells as Colitis Drivers
New findings suggest B cell levels can predict the risk of inflammation for patients receiving cancer immunotherapy.
Updated on Sept. 22, 2026 in Cancer
Live Poll
Does understanding treatment side effects in advance make you feel more confident about receiving new therapies?
Researchers at the University of Texas MD Anderson Cancer Center discovered that B cells trigger colitis during immune checkpoint inhibitor treatment. Their study indicates that pre-treatment B cell levels correlate with an increased risk of intestinal inflammation.
Why it matters
Understanding this inflammatory cascade allows clinicians to identify high-risk patients before therapy begins. This discovery provides a potential target to prevent severe side effects that often disrupt cancer treatment.
Preclinical models showed that depleting B cells prior to treatment significantly reduced both intestinal damage and subsequent inflammatory T cell responses. Researchers also observed altered gut microbiomes in models susceptible to colitis development.
The players
University of Texas MD Anderson Cancer Center
This is a world-renowned academic medical center that serves as a global leader in cancer research and patient care.
Cleveland Clinic
This is a major nonprofit academic medical center that integrates clinical and hospital care with research and education.
The details
The study revealed that B cell dysregulation initiates an inflammatory cascade that leads to colon tissue damage. Researchers also demonstrated that fecal microbiota transplantation can reduce the severity of colitis in preclinical models.
Timeline
September 22, 2026: The study findings were published in Cell Reports.
The Big Picture
This study advances the MD Anderson Cancer Center immunotherapy side-effect research initiatives by identifying a primary driver of toxicity. It marks a departure from traditional models that focused primarily on T cells, shifting the scientific focus toward B cells in the development of colitis.
Patients preparing for immune checkpoint inhibitor therapy may soon benefit from new blood-based screening tests to assess their colitis risk. These findings could eventually lead to preventive clinical interventions that protect intestinal health during cancer treatment.
The takeaway
Clinicians may soon use baseline B cell measurements to personalize immunotherapy regimens for cancer patients. Modifying gut health through targeted therapies or microbial intervention represents a promising frontier for reducing treatment-related complications.
Further reading
For more information on current treatment safety and research, visit the Cancer section.
More information
View the complete peer-reviewed research article01047-8) published in Cell Reports.
Source note: This article includes information reported by News-Medical.
Live Poll
Does understanding treatment side effects in advance make you feel more confident about receiving new therapies?
